Sign inJoin waitlistJoin the waitlist

TC

Timothy Cannon

Sheridan Director, Molecular Tumor Board · Inova Schar Cancer Institute

Credentials: · · · ·

History

Gastrointestinal Cancer Program · Inova Schar Cancer Institute
Present
Hematology/Oncology Section · Inova Fairfax Hospital Campus
Present

Hematology and Medical Oncology
NYU Grossman School of Medicine
2008–2011
Internal Medicine
George Washington University School of Medicine
2005–2008
Robert Wood Johnson Medical School
2001–2005
University of Utah
Brigham Young University

Research

Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine
Vaccine · 1996 · 180 citations
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal of Clinical Oncology · 2021 · 158 citations
Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience
Vaccine · 1999 · 105 citations

Richard Schilsky
12 papers
Ramya Thota
8 papers
PP
Phillip Pittman
7 papers
Eugene Ahn
6 papers
John Deeken
6 papers
Arthur Winer
5 papers · 2 as a fellow
Herbert Duvivier
5 papers
Raymond Wadlow
5 papers
Alissa Marr
4 papers
DB
Deepti Behl
4 papers
Kathryn Mileham
4 papers
Olatunji Alese
4 papers

Clinical trials

The Purpose of This Study is to Determine the Frequency of Colorectal Cancer in Male and Female Endurance Athletes Between the Ages of 35 and 50
Principal investigator · Completed
Inova Health Care Services
2022–2025
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2023–2030
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Site PI · Recruiting · Phase 2
American Society of Clinical Oncology
2016–2028